Gillian F Moore

A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract

M. V. D. van den Brink, J. Shia, A. Alousi, 2020 .

A phase 2 study of Interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract.

M. Perales, M. V. D. van den Brink, S. Devlin, 2022, Blood.

Preservation of fecal microbiome is associated with reduced severity of Graft-versus-Host Disease.

Y. Taur, M. Perales, M. V. D. van den Brink, 2022, Blood.